Immunologic effects of F16-IL2 therapy.

Slides:

Advertisements

Similar presentations

Supplementary Figure S1

Advertisements

WT1-specific T-cell responses in high-risk multiple myeloma patients undergoing allogeneic T cell–depleted hematopoietic stem cell transplantation and.

Activation of NK cells during the early stage of allergic and fibrotic lung inflammation. Activation of NK cells during the early stage of allergic and.

by Manuella L. Gomes Ochtrop, Sigune Goldacker, Annette M

How I treat LGL leukemia

Clonal bias of CD56−CD16+ NK cell subpopulations.

by Christopher Dittus, and Dana Semmel

Clinical response to F16-IL2 and LDAC in patients with AML bone marrow involvement. Clinical response to F16-IL2 and LDAC in patients with AML bone marrow.

Morphological analyses of peripheral blood and bone marrow cells isolated from leukemic mice. Morphological analyses of peripheral blood and bone marrow.

K. T. D. Thai, J. A. Wismeijer, C. Zumpolle, M. D. de Jong, M. J

by Karthik A. Ganapathi, Danielle M. Townsley, Amy P. Hsu, Diane C

Interleukin (IL)-1β-producing cells in peripheral blood mononuclear cells (PBMCs). Interleukin (IL)-1β-producing cells in peripheral blood mononuclear.

Targeting CD138−/CD20+ Clonogenic Myeloma Precursor Cells Decreases These Cells and Induces Transferable Antimyeloma Immunity Lawrence G. Lum, Archana.

Timely follow-up of a GATA2 deficiency patient allows successful treatment Sara Ciullini Mannurita, MSc, Marina Vignoli, PhD, Gloria Colarusso, MD, PhD,

by Enrico Lugli, Carolyn K. Goldman, Liyanage P

Detection of Trisomy 12 and Rb-Deletion in CD34+ Cells of Patients With B-Cell Chronic Lymphocytic Leukemia by B. Gahn, C. Schäfer, J. Neef, C. Troff,

Histopathologic features (all images at ×10 magnification).

Selective Ablation of Acute Myeloid Leukemia Using Antibody-Targeted Chemotherapy: A Phase I Study of an Anti-CD33 Calicheamicin Immunoconjugate by E.L.

Figure 3 Immunohistochemical analyses of positive and negative Epstein-Barr virus (EBV) control tissues using immunostaining Immunohistochemical analyses.

by Huifei Liu, and Shafinaz Hussein

Combined CD4+ Donor Lymphocyte Infusion and Low-Dose Recombinant IL-2 Expand FOXP3+ Regulatory T Cells following Allogeneic Hematopoietic Stem Cell Transplantation

LEF-1 is a prosurvival factor in chronic lymphocytic leukemia and is expressed in the preleukemic state of monoclonal B-cell lymphocytosis by Albert Gutierrez,

Adoptive Cellular Therapy using Cells Enriched for NKG2D+CD3+CD8+T Cells after Autologous Transplantation for Myeloma Kenneth R. Meehan, Laleh Talebian,

Elevated Numbers of Immature/Transitional CD21− B Lymphocytes and Deficiency of Memory CD27+ B Cells Identify Patients with Active Chronic Graft-versus-Host.

Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report by Richard L.

Frequencies of immune cell types show much stronger variations between tumor types in the tumor infiltrate compared with the spleen and tumor-draining.

ALT-803 administration increases peripheral blood cell counts of lymphocyte subsets in cynomolgus monkeys. ALT-803 administration increases peripheral.

Isolating CD8+ T cells from lupus-prone mice.

by Geling Li, Emily Waite, and Julie Wolfson

Volume 23, Issue 1, Pages (January 2015)

Rapid response to F16-IL2 and LDAC in disseminated extramedullary AML

Evaluation of clinical responses after infusion of CART19 cells

mpJX-594 effects on tumor burden and leukocyte influx.

Figure 2 Peripheral blood lymphocyte subset counts during dimethyl fumarate treatment(A) Lymphocyte subsets were obtained at baseline (n = 21) and at month.

Pure Erythroid Leukemia Presenting in a HIV-Positive Patient

Figure 2 Evolution of blood cell counts during interleukin (IL)–7 therapy Evolution of blood cell counts during interleukin (IL)–7 therapy The leukocyte.

Figure MRI brain comparison prior and after treatment and brain biopsy findings MRI brain comparison prior and after treatment and brain biopsy findings.

Figure 1 Peripheral blood lymphocyte counts during dose titrationB-lymphocyte (CD19+; A) and total lymphocyte (CD45+; B) counts (cells/µL) in peripheral.

CD4+CLA+CD103+T cells from human blood and skin share a functional profile. CD4+CLA+CD103+T cells from human blood and skin share a functional profile.

Analysis of tumor-infiltrating CD8+ T cells and effect of T and NK cell depletion. Analysis of tumor-infiltrating CD8+ T cells and effect of T and NK cell.

Combined BRAFi and anti-CTLA4 administration leads to prolonged antitumor immunity in a patient with metastatic melanoma. Combined BRAFi and anti-CTLA4.

Leukemic blasts express a “hypoxia signature

Geographic colocalization of PD-L1+ tumor cells with infiltrating immune cells in MCC. The predominant pattern of tumor cell PD-L1 expression is at the.

Figure 4 Cell count of selective immune cell subpopulations during alemtuzumab Cell count of selective immune cell subpopulations during alemtuzumab Absolute.

Colony-forming capacity of CD34+ cells with and without CLL-1 expression. Colony-forming capacity of CD34+ cells with and without CLL-1 expression. CD34+

IL6 mRNA is not detected in metastatic prostate cancer cells.

CD8, galectin-3, galectin-9, and the M1/M2 ratio are associated with a longer survival. CD8, galectin-3, galectin-9, and the M1/M2 ratio are associated.

Endothelial cells/microvasucles are increased in prostate cancer versus normal tissues. Endothelial cells/microvasucles are increased in prostate cancer.

Increase in proliferation and activation of immune cells in peripheral blood after NKTR-214 treatment. Increase in proliferation and activation of immune.

ADU-S100–mediated tumor clearance is dependent on CD4+, CD8+ T cells, and NK cells. ADU-S100–mediated tumor clearance is dependent on CD4+, CD8+ T cells,

In vivo AraC treatment does not induce any consistent changes in CD34+/−CD38+/− phenotypes nor in quiescent leukemic cells but increases apoptotic cell.

ALT-803 stimulates proliferation and activation of human NK cells and T cells in vitro. ALT-803 stimulates proliferation and activation of human NK cells.

Intratumoral tertiary lymphoid aggregates observed in PDACs from Panc GVAX–treated patients. Intratumoral tertiary lymphoid aggregates observed in PDACs.

Immunologic and pharmacokinetic studies.

ESKM treatment does not affect leukocyte or HSC counts in HLA-A

Evaluation of clinical responses after infusion of CART19 cells

Immunohistochemical staining for FOXO3a of breast cancer tumor tissues

Intratumoral changes in critical lymphocyte populations and numbers after NKTR-214 treatment. Intratumoral changes in critical lymphocyte populations and.

PD-1 and CD103 are coexpressed on CD8+ T cells but demonstrate distinct mechanisms of regulation. PD-1 and CD103 are coexpressed on CD8+ T cells but demonstrate.

Anti-CD40 activates TAMs and recruits inflammatory monocytes.

Specific reaction with MIB1, M30, and CD31 monoclonal antibodies in primary human cervical carcinoma before (A, C, and E) and after (B, D, and F) Tam treatment.

Analysis of absolute CD4+ cytokine+ cell numbers pre- and post-ART.

Constitutive expression of JAK3M511I and HOXA9 leads to development of both AML and T-ALL in vivo. Constitutive expression of JAK3M511I and HOXA9 leads.

Schedule-dependent impact of costimulated activated T-cell transfer on T-cell reconstitution after tandem stem cell transplant. Schedule-dependent impact.

Vaccination schedule. Vaccination schedule. Vaccinations were given in cycles; each cycle consisted of four injections (vertical lines). Up to four additional.

IL35 regulation of tumor growth is accompanied by suppression of CD4+ effector T-cell activity and expansion of Tregs. IL35 regulation of tumor growth.

Immunohistochemical determination of TIM-3 expression in ccRCC.

Cell counts of immune infiltrate and expression of galectin-1 and galectin-3 in the short-, medium-, and long-term survival cohorts. Cell counts of immune.

MDSC population in patient peripheral blood.

Trametinib and combination decrease T-lymphocyte proliferation.

Presentation transcript:

Immunologic effects of F16-IL2 therapy. Immunologic effects of F16-IL2 therapy. A, changes in peripheral blood lymphocyte subpopulations during therapy with F16-IL2 and LDAC as revealed by flow-cytometric analysis. The most prominent increase was observed in CD16+/CD56+ NK cells and CD8+ lymphocytes. Triangle arrows indicate infusions of F16-IL2. B, photographs of May-Grünwald–Giemsa–stained peripheral blood smears show activated lymphocytes and large granular lymphocytes (obtained from patient 2 after two infusions of F16-IL2). C, immunohistochemical staining of pre- and posttherapeutic bone marrow biopsies showed a massive influx of CD3+ and CD8+ lymphocytes as exemplified in patient 2 (CD3 staining) and patient 4 (CD8 staining). D, flow-cytometric analyses of bone marrow aspirates showed a 10-fold increase of CD8+ lymphocytes and a 38-fold increase of NK cells at the end of the first cycle (patient 4). E, cell clusters reminiscent of immunological synapse formation between activated lymphocytes and leukemic cells could be observed frequently in the bone marrow. ALC, absolute lymphocyte count. Christoph Schliemann et al. Cancer Immunol Res 2015;3:547-556 ©2015 by American Association for Cancer Research